Most pregnant women at risk of for infection with Plasmodium vivax live in the Asia-Pacifi c region. However, malaria in pregnancy is not recognised as a priority by many governments, policy makers, and donors in this region. Robust data for the true burden of malaria throughout pregnancy are scarce. Nevertheless, when women have little immunity, each infection is potentially fatal to the mother, fetus, or both. WHO recommendations for the control of malaria in pregnancy are largely based on the situation in Africa, but strategies in the Asia-Pacifi c region are complicated by heterogeneous transmission settings, coexistence of multidrug-resistant Plasmodium falciparum and Plasmodium vivax parasites, and diff erent vectors. Most knowledge of the epidemiology, eff ect, treatment, and prevention of malaria in pregnancy in the Asia-Pacifi c region comes from India, Papua New Guinea, and Thailand. Improved estimates of the morbidity and mortality of malaria in pregnancy are urgently needed. When malaria in pregnancy cannot be prevented, accurate diagnosis and prompt treatment are needed to avert dangerous symptomatic disease and to reduce eff ects on fetuses.
Introduction
Most pregnant women at risk for infection with Plasmodium vivax live in the Asia-Pacifi c region, which consists of the WHO South-East Asia and Western Pacifi c regions. These areas generally have low transmission of Plasmodium falciparum and women have little acquired immunity against malaria. 1 Many countries in the AsiaPacifi c region have successfully reduced prevalence of malaria and several national malaria control programmes have adopted elimination of malaria as an objective. However, malaria infection in pregnancy is commonly not perceived as a major health problem. Pregnant women are a vulnerable population, 2 but in many areas their malaria-related morbidity and mortality are unknown. 3 Specifi c treatment guidelines or prevention strategies for malaria in pregnancy either do not exist or have only recently been introduced. [4] [5] [6] Interventions recommended by WHO for the control of P falciparum malaria during pregnancy are largely based on fi ndings from sub-Saharan Africa, where P falciparum is the dominant species, transmission is high, and Anopheles gambiae is the main vector. 7 Strategies for the Asia-Pacifi c region are complicated by several factors: diversity in malaria transmission and vector behaviour, 8 coexistence of P vivax, 9 multidrug-resistant parasites, 10, 11 substandard and counterfeit drugs, 12 cross-border movement of migrants, 2 ethnic minorities that have little access to health care, 2 and the political climate in some countries. 2 In this Review of the 20 countries in the Asia-Pacifi c region with malaria transmission, 13 we summarise both published (126 reports) and unpublished (six studies) data for malaria in pregnancy identifi ed from various databases and the World Malaria Report 14 (webappendix pp 1-4), focusing on epidemiology, clinical presentation, treatment, and prevention of malaria in pregnancy. Additionally, we identify gaps in the evidence to assist identify priorities for future research in the Asia-Pacifi c region.
Epidemiology Malaria transmission
Malaria transmission in the Asia-Pacifi c region is highly hetero geneous. Generally, transmission is low (entomological inoculation rate of P falciparum is less than one infective bite every year), unstable (with year-to-year variation and epidemics), highly focal, and seasonal, and it mostly occurs in rural areas. 15 Nonetheless, several countries have foci of entomological inoculation rates of more than ten infectious bites per year, indicating high transmission. 16 Of the total population at risk (more than 2·2 billion people), a quarter lives in areas of moderate or high P falciparum malaria transmission. 1, 13, 17 Large vari ations in malaria transmission are present not only within countries, but also within regions. For example, malaria in Thailand occurs in forested pockets along international borders. 18, 19 Urban malaria is rare, except in India. 3, 20 All these variations have important eff ects on the acquisition of natural immunity to malaria. P vivax malaria could re-emerge in areas where it was eliminated 21 or become prevalent where P falciparum is controlled. 19, 22 The prevalence of P vivax is diffi cult to estimate because P vivax is often under-reported in coinfections with P falciparum and relapses from liver stages are unrelated to vector activity. 23, 24 
Pregnancies at risk
In 2007, roughly 75 million women became pregnant in the Asia-Pacifi c region, 1 but these women were mostly in India and China. Because of the focal nature of malaria transmission, 25 the substantial seasonality, and the variable strength of malaria control programmes, risk estimates have to be refi ned and combined with clinical data to be accurate and useful, and to minimise bias. In pregnancy, women and their babies are at risk of malaria's deleterious eff ects for the 40 weeks of gestation. However, longitudinal data collection is needed to estimate the true burden of malaria. Most investigators report rates of confi rmed malaria infection at enrolment in the antenatal clinic (table 1) or at delivery  (table 2) ; only a few record cumulative proportions or incidence rates.
Four studies [27] [28] [29] 32 that showed a high proportion of women with malaria (three from India and one from Laos) included only pregnant women with fever or a See Online for webappendix Review history of fever. After exclusion of these studies, malaria smears to detect parasites in maternal peripheral blood established that the median reported proportion of pregnant women infected with malaria was 15·3% (range 1·2-40·8) in antenatal clinics (nine studies; webappendix p 5) and 8·1% (range 1·6-18·5) in delivery rooms (12 studies; webappendix p 7). The median proportion of reported placental parasitaemia was 11·0% (range 1·4-29·1; 12 studies; webappendix p 8).
Screening surveys, however, are very prone to variation because they provide only an estimate of the prevalence of malaria infections in a short period. The wide range of positivity rates is a result not only of diff erences in transmission intensity, but also of discrepancies in methods or season when surveys are done. For example, at antenatal screenings every week at the Thai-Burmese border, which are essentially weekly cross-sectional surveys, the mean malaria prevalence in one clinic was 0·85% (95% CI 0·83-0·87; range 0-3·1) for P falciparum and 3·18% (95% CI 3·14-3·22; range 0-8·3) for P vivax in 2008 (unpublished). However, the cumulative proportions of infected women in the same population in the same year were 6·8% (50 of 733 women) for P falciparum and 16% (119 of 733 women) for P vivax (unpublished). In this setting in 2008, the median number of consultations per woman was [14] [15] [16] [17] [18] [19] [20] .
To establish the true burden of malaria in pregnancy, longitudinal follow-up of pregnant women is preferable. Investigators of 11 studies have followed up the same women during pregnancy, providing a cumulative proportion of malaria episodes (table 3) . In ten studies that showed the number of women with malaria, the median proportion of infected women was 36·5% (range 6·0-64·0). Women can be infected in all trimesters 33, 47, 48 and in any pregnancy, although fi rst-time mothers are at higher risk than are others in most studies. 20, 48 In fi ve studies in India, 27 Review women with fever or a history of fever (n=974) were infected (with P falciparum or P vivax) signifi cantly more frequently, with signifi cantly higher parasitaemia, than were non-pregnant women of child-bearing age with fever or a history of fever in the same area and study period. Women with a history of malaria in pregnancy are at increased risk for another episode during pregnancy.
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Plasmodial species
In the reviewed studies, P vivax caused a median of 28·5% (range 5-100) of malaria infections detected at antenatal clinics (13 studies; table 1). Plasmodium ovale and Plasmodium malariae were present in all sites, but studies with PCR diagnosis suggest that these species are probably under-reported when microscopy is used.
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Plasmodium knowlesi was not reported in any pregnancy Review studies. At the Thai-Burmese border, the incidence of malaria has fallen from more than three infections per pregnant woman-year to less than 0·5 in the past 20 years, 22 and distribution of malaria species has changed substantially (fi gure 1, table 3). Most malaria infections are now caused by P vivax, 9, 48, 50, 51 and mixed infection is uncommon (tables 1-3). A protective eff ect of P vivax infection against subsequent episodes and severity of P falciparum malaria was noted in Thailand. 9, 55 However, an acute episode of P falciparum could trigger a relapse of a previously acquired P vivax infection. 56 Therefore, as the incidence of P falciparum declines, the number of P vivax episodes caused by relapses will eventually also decrease.
Clinical presentation Diagnosis
The most common method used to detect malaria parasites is microscopy of stained blood smears (tables 1-3). A skilled and well-equipped microscopist can detect 15 parasites per μL of blood, which corresponds to a total biomass of 100 million parasites. 57 In fi eld situations, however, equipment might not be ideal and experienced microscopists are often overloaded with work. No published data exist for quality control of malaria smears from pregnant women. Rapid diagnostic tests are practical because they do not demand long training, good infrastructure, or electricity, but they might not have the sensitivity needed in pregnancy. 36, 57 Studies done in Jharkhand and Chhattisgarh states in India showed that rapid diagnostic tests were more sensitive than were malaria smears for the detection of malaria in the peripheral blood of women in labour and in placental infection (table 2) . 36 However, these fi ndings could be explained by the slow elimination of the histidine-rich-protein-2 detected by the Paracheck-Pf rapid diagnostic test used.
PCR is also used for genotyping and detection of malaria parasites and is more sensitive than is microscopy. 57 At present, there is very little evidence for PCR diagnostic assessment in pregnancy in the Asia-Pacifi c region. In available studies, PCR detected more P falciparum than did malaria smear (tables 1, 2). Continuing studies in India (Madhya Pradesh and Chhattisgarh states) and eastern Indonesia showed that PCR detected up to twice as many P vivax and P falciparum episodes as did malaria smears or rapid diagnostic tests (unpublished).
In areas with early detection and treatment with artemisinin-based combination therapies, placental malaria is confi ned to pregnancies with concurrent maternal peripheral parasitaemia. 38, 39 Furthermore, sites at the Thai-Burmese border and Indonesia that use artemisinin-based combination therapies in pregnancy have a lower ratio of placental to peripheral smear positivity than do sites in India and Papua New Guinea, where chloroquine or sulfadoxine-pyrimethamine, or both, are used (table 2, fi gure 2). In India and Papua New Guinea, P falciparum resistance to chloroquine and sulfadoxine-pyrimethamine is high. 20, 29, 35, 36, 40, 41, 42 Despite diff erences in transmission, this fi nding could be a result of increased clearance of parasites from the maternal and placental blood by the more eff ective artemisinin-based combination therapies. 
Review Anaemia
The anaemia burden in pregnancy is profound: about 75% of women attending antenatal clinics in India, 20, 47 Nepal, 31 Papua New Guinea, 58 or at the Thai-Burmese border 50 develop anaemia at some stage of pregnancy. Malaria-induced destruction of red blood cells aggravates any underlying nutritional anaemia, intestinal parasitisation, or red-cell inherited disorders such as haemoglobinopathies. 15 In low-transmission areas, mild anaemia predominates, whereas in areas of high transmission, 10% of pregnant women might develop severe anaemia. 48, 50, 58, 59 Comparisons between studies are diffi cult because of diff erences in anaemia defi nitions, iron supplementation, and use of chemoprophylaxis. Both falciparum and vivax malaria worsen anaemia, but P falciparum has a stronger eff ect than does P vivax (webappendix p 9). 9, 31, 37, 60 Even asymptomatic malaria episodes could cause anaemia, 37 and women during their second or subsequent pregnancies are more anaemic than are women in their fi rst pregnancy. 37, 42, 48, 50 Severe maternal anaemia during pregnancy increases risk of premature labour 37, 41 and stillbirth, 61, 62 and reduces birthweight. 37, 48, 58 Data from Thailand suggest that risk of P vivax malaria increases after start of haematinic supplementation (iron and folate). 63 Defi ciency of glucose-6-phosphate dehydro genase is common in the Asia-Pacifi c region, but its interaction with the risk of malaria in pregnant women and anaemia is unknown. Although southeast Asian ovalocytosis and α thalassaemia protect young children in Papua New Guinea against cerebral malaria, 64,65 neither genetic trait seems to change the eff ects of malaria in pregnancy. 42, 59, 66 The risk of thrombocytopenia is more than two times higher in pregnant women with malaria than in non-pregnant women infected with malaria, but this disorder is rarely severe (less than 10 000 platelets per μL). 60, 67 Prompt antimalarial treatment can normalise platelet counts within a week. 67 Malaria-induced thrombocytopenia and anaemia could increase the risk of post-partum haemorrhage. 68 
Comorbidities
A relation between placental malaria and pre-eclampsia is suggested by studies from highly endemic areas, 69 but only one report is from the Asia-Pacifi c region after an epidemic in 1935. 70 In sub-Saharan Africa, the burden of malaria has been exacerbated by HIV. 71 No reports of HIV and malaria in pregnancy come from the Asia-Pacifi c region. Investigators have recorded an association between low rates of P falciparum or P vivax infection in pregnant women and co-infection with Ascaris lumbricoides. 72 Hookworm infestation, however, is associated with an increased risk of P falciparum infection and low birthweight, and high hookworm counts are linked with anaemia. [72] [73] [74] An integrated approach to malaria and helminth control has been promoted for pregnant women 75 and should be tailored according to the local prevalence and intensity of geohelminths and malaria, and anaemia burden. 72 About 10% of women with malaria had rickettsial coinfection in a cohort study done at the Thai-Burmese border.
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Severe malaria and mortality
Detailed malaria-attributable maternal mortality rates are rarely reported. However, in three districts in India, 22 (23%) of 95 maternal deaths were attributed to malaria between 2004 and 2006, which is a total mortality rate of 722 per 100 000 livebirths. 77 Malaria was the most 
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Review common cause of maternal death during pregnancy (11 of 23 deaths; 48%) and was the cause of six (23%) of 26 post-partum maternal deaths. Before introduction of malaria-control programmes for pregnant women in western Thailand, fi ve (1%) of 500 pregnant women died of malaria in 1 year. 48 Signs that are rare in childhood malaria-eg, acute renal failure, pulmonary oedema, and severe jaundice-are common manifestations of severe malaria in adults. 55, 78 Death during pregnancy or just after delivery occurs because of cerebral malaria, renal failure, hepatic impairment, severe anaemia, hypoglycaemia (worse with quinine treatment), uncontrollable post-partum haemorrhage, or acute respiratory distress syndrome. 30, 48, 70, [78] [79] [80] Pregnant women have a three-times higher risk of severe malaria than do non-pregnant women. 53, 55 In eight studies of severe malaria in pregnancy (n=227), 52 ,78-84 the median maternal mortality was 39% (range . This wide range is related to the broad WHO defi nition of severe malaria: the lowest mortality was reported in pregnant women whose only sign of severity was hypoglycaemia. 79 By contrast, all women with renal failure died. 78 In an autopsy study of 277 women in India, 85 10% of maternal mortality was attributable to infectious diseases, of which tuberculosis, malaria, and leptospirosis were most common. In reports from India, 35, 60, 86 women with severe vivax malaria had very poor pregnancy outcomes and maternal mortality was reported. An actionfor-survival programme dedicated to care of pregnant women with malaria greatly reduced mortality in a regional hospital in Thailand, where malaria was the most common cause of maternal death during the 1980s. 87 Early detection and treatment at the Thai-Burmese border has eliminated maternal death and severe malaria in women who participate in weekly screening. 48 
Eff ect on fetuses and infants
The median reduction in birthweight in the reviewed studies was 150 g (range 1-650; fi gure 3) for P falciparum or mixed infections, 20, 29, 36, 37, 41, 42, 44, 47, 48, 88, 89 and 108 g (107-310) for P vivax malaria. 9, 29, 37 Birthweight reduction occurs mainly in fi rst pregnancies with P falciparum malaria but also in subsequent pregnancies, and even with one episode of P vivax or P falciparum malaria.
9,39,48 Both symptomatic and asymptomatic malaria episodes increase the risk of low birthweight, although symptomatic infections in pregnancy might have a larger eff ect than does asymptomatic disease, particularly on premature delivery. 37, 48, 50 Malaria reduces birthweight independently of anaemia. 58 Macgregor 90 identifi ed an exponential fall in the risk ratio for low birthweight in women during their fi rst pregnancy after a reduction in malaria transmission in the Solomon Islands. This Review does not address how malaria reduces birthweight, particularly with P vivax, which does not seem to cytoadhere in the placenta to the same extent as P falciparum.
Low birthweight alone is not a reliable indicator of malaria's eff ect on fetal growth; other information is needed, such as parents' anthropometrics, gestational age, neonatal length, and head circumference. 91 Gestational age estimation is notoriously diffi cult in resource-poor settings. In the studies shown in fi gure 3, neither ultrasound dating (early gestation ultrasound is the gold standard for gestational age estimation) nor fetal size charts to diagnose intrauterine growth restriction were available. 91 Fetal distress (measured by cardiotocography or meconium staining of the amniotic fl uid) is an important feature of symptomatic falciparum malaria and severe anaemia, both before and during labour. 62, 79 In areas where women attend antenatal clinics late in pregnancy or only for delivery, miscarriage rates are probably underestimated. Stillbirth and spontaneous abortion can result from infection with P falciparum or P vivax, and from severe anaemia. 27, 37, 58, 61, 62, 80 However, in an early report 9 from an intense antenatal malaria screening and prompt-treatment programme at the Thai-Burmese border, P vivax infection was not associated with premature labour, miscarriage, or stillbirth. By contrast, of 25 unwell Indian pregnant women admitted to hospital because of P vivax malaria, more than half of the pregnancies ended with these adverse outcomes. 60 This fi nding draws attention to the importance of early detection and treatment of any malaria in pregnancy to prevent the eff ects of symptomatic disease. Further studies into eff ects of malaria infection in the fi rst trimester are needed.
Congenital malaria occurs when malaria parasites cross the placenta either during pregnancy, 92 or at delivery. 93 Congenital P falciparum or P vivax malaria is a potentially serious complication of symptomatic and asymptomatic infection at any time in pregnancy, but neonatal symptoms are not typical for malaria and usually become evident only 10-30 days after birth. 92, 93 Table 4 shows prevalence of congenital malaria. There are no WHO criteria for diagnosis or recommendations for drug dosing in treatment of neonates with severe malaria. Severe disease in neonatal P falciparum and P vivax infections is common and can be characterised by severe anaemia and respiratory distress. All sick neonates in malaria endemic regions should have a malaria smear. 92, 96, 102 Additionally, malaria in pregnancy directly aff ects infant survival. In Thailand, maternal infection (including malaria) in the week before delivery is the only risk factor for infant death in the fi rst 3 months of life, after adjustment for birthweight and gestational age. 50 Anaemia was an independent risk for infant death in early studies in Thailand, 49, 106 but a 2001 investigation did not confi rm this fi nding. 50 This diff erence might be explained by the multifactorial causes of anaemia in Thailand and codefi ciency of vitamin B₁ in infants, a major cause of infant mortality. 107 Although treatment 38 and prevention 51 for malaria had no adverse eff ects on infant growth and Review neurodevelopment at age 1 year in a study in Thailand, no studies of the interaction with nutritional status, child development, and the placental and fetal epigenome exist. However, high rates of childhood stunting were reported in Papua New Guinea in individuals exposed to malaria in utero during an epidemic.
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Treatment
The Asia-Pacifi c region has been aff ected by the emergence of antimalarial-drug resistance. 10, 11, 37, 109 Most countries have updated their national guidelines to match WHO recommendations of artemisinin-based combination therapies in the second and third trimester of pregnancy. Proactive operational guidelines include use of artemisininbased combination therapies in pregnancy in parts of Melanesia for both P falciparum and P vivax. 37 Trials of antimalarials in pregnancy for infection with P falciparum and P vivax have been done (table 5) , but most occurred in one site only. No researchers have randomly assigned pregnant women in the fi rst trimester.
No large recent studies of chloroquine effi cacy in treatment of vivax malaria in pregnancy are available, 113, 121 but Indonesia, the Solomon Islands, Papua New Guinea, and Vanuatu have changed their national treatment to artemisinin-based combination therapies because of the high prevalence of chloroquine-resistant parasites in the general population.
122 P vivax has liver stages (hypnozoites) that cause recurrent blood stage infections (relapses). Primaquine-the only drug eff ective against liver stages-is contraindicated in pregnant and lactating women because fetal red blood cells are susceptible to haemolysis. 123 Chloroquine remains the drug of choice for uncomplicated P knowlesi, P malariae, and P ovale. 124 In a small pharmacokinetic study in Papua New Guinea, 120,121 13 women were treated with a combination of sulfadoxine-pyrimethamine and chloroquine, which had a low cure rate of 62% (table 5) . Chloroquine had no eff ect against P falciparum in pregnant women in India during a malaria epidemic in 1997-98. 47 The mean cure rate of quinine monotherapy in seven studies (845 patients; table 5) was 73·2% (SD 14·1), probably because of resistance and, in one study, 48 poor adherence to treatment. When clindamycin was added to quinine and treatment was supervised, 116 cure rate improved to 100%. However, the gametocyte carriage rate after treatment in women who did not have these sexual stages on admission was 13 times higher than it was in women given a 7 day course of artesunate monotherapy. 109 Mefl oquine monotherapy had a cure rate of 72% in one investigation, 111 but in combination with artesunate it can reach 100%. 112, 115 In a study at the Thai-Burmese border, 38 125 pregnant women treated with artemetherlumefantrine for 3 days had a cure rate of only 87%, which was inferior to artesunate monotherapy for 7 days. Other artemisinin-based combination therapies (dihydro artemisinin-piperaquine;
artesunate-clindamycin; and artesunate, atovaquone, and proguanil) have cure rates of more than 90% (table 5) . Treatment of severe malaria in pregnant women has not been investigated, although these patients were not excluded from the SEAQUAMAT trial. 84 However, intravenous artesunate is the WHO recommended treatment of choice, irrespective of trimester. 84, 125 In practice, health workers providing antimalarials either might not prescribe correct doses 126 or might be afraid to give drugs to pregnant women because of concerns about potential teratogenic eff ects or abortion. 126, 127 Recommendations about regimens to use in treatment of malaria during pregnancy are notably absent in many settings. 128 A major disconnect has been identifi ed between routine antenatal practices and known strategies to prevent and treat malaria in pregnancy. 128 13 (62%) of 21 studies into antimalarial pharmacokinetics in pregnancy worldwide have been done in the Asia-Pacifi c region. Many drugs have been studied: quinine; 129 and azithromycin. 141 Several researchers report reduced drug concentrations in pregnant women's blood after standard dosing of antimalarial drugs and recommend the need for dose alterations, especially for lumefantrine, chloroquine, and proguanil.
Prevention
Unlike sub-Saharan Africa, prevention of malaria in pregnancy is not emphasised in national guidelines for malaria in the Asia-Pacifi c region. Longlasting Allen 1998 41 Benet 2006 42 Kaushik 1992 88 Nosten 1991 48 Poesproprodjo 2008 37 Singh 1999 29 Brabin 1990 Primip 89 Brabin 1990 Multip 89 Hamer 2009 Review insecticide-treated bednets are distributed in all countries, 14 but reports in the past 3 years have shown low availability or use by pregnant women. 26, 34, 128 Case management is available everywhere, but in reality malaria smears are obtained from pregnant women only when fever or other malarial symptoms are present and these symptoms are often not checked by health workers. 128 Papua New Guinea is the only country with a policy for intermittent preventive treatment in pregnancy.
However, the policy has yet to be implemented in antenatal clinics. More than 10 years have passed since the reduction in incidence of P falciparum in pregnant women at the Thai-Burmese border because of early detection and treatment of the general population with artemisinin-based combination therapies (eg, mefl oquine-artesunate). 22 These factors have had a far greater eff ect than have chemoprophylaxis, 49 bednets, 106 or skin repellents for pregnant women. Review Vector-control measures aiming for total-population coverage are benefi cial for pregnant women. Insecticidetreated bednets and indoor residual spraying reduce malaria transmission. 143 In the only vector-control investigation in pregnancy in the Asia-Pacifi c region-a bednet study-fewer women in the experimental group had peripheral parasitaemia than in the group with untreated nets, but the diff erence was not signifi cant. 106, 144 The parasite density and frequency of anaemia was lower in the pregnant women with treated nets than in those with untreated nets. No eff ect on birthweight or premature labour was recorded. 106 In India's Jharkhand state, most women report having untreated bednets in their homes, but only 3·3% had insecticide-treated bednets. 20 Several studies show that free treated nets for pregnant women have not been distributed despite government policy, that women in their fi rst pregnancy are less likely to own treated bednets than are those in subsequent pregnancies, and that priority to sleep under the treated net is given to young children. 34, 127, 145, 146 Review dawn, when they may already be awake and active, potentially restricting the protective eff ect of treated nets. 147 Mosquito repellents with N,N-diethyl-metatoluamide (DEET) are safe in pregnancy, 148, 149 can reduce exposure to insect bites, 148 and resulted in a nonsignifi cant reduction in the incidence of P falciparum infection in pregnant women in one possibly underpowered study. 142 Mefl oquine chemoprophylaxis gave 86% protection against P falciparum and complete protection against P vivax infection in a double-blind, placebo-controlled study 49 at the Thai-Burmese border when mefl oquine was still fully eff ective. A retrospective analysis of chloroquine chemoprophylaxis in pregnant women from Papua New Guinea showed that the drug did not reduce placental or maternal peripheral blood infection at delivery where resistance was high. 41, 150 In a double-blind, randomised controlled trial of chloroquine chemoprophylaxis at the Thai-Burmese border, 51 prophylaxis prevented P vivax episodes, but had no eff ect on P falciparum in pregnancy. In Papua New Guinea, prevalence and density of placental and maternal peripheral blood parasitaemia did not seem to be aff ected by chloroquine chemoprophylaxis during pregnancy, but haemoglobin concentration was higher after delivery in women who took chloroquine than in those who did not. 41 Weekly chloroquine prophylaxis resulted in poor parasite clearance despite good compliance in a longitudinal investigation in Papua New Guinea. 33 Few pregnant women use chloroquine chemoprophylaxis in India, Papua New Guinea, and the Solomon Islands. 20, 34, 151 The only data for intermittent preventive treatment in pregnancy from the Asia-Pacifi c region are the pharmacokinetics of chloroquine and sulfadoxine-pyri methamine (three chloroquine tablets every day for 3 days, and one sulfadoxine-pyrimethamine dose), which prevented all vivax episodes, but fi ve of 13 women had another P falciparum infection within 28 days of treatment. 120, 121 The rationale of intermittent screening and treatment is to screen pregnant women frequently to detect and treat malaria parasitaemia at an early stage and use an eff ective drug to prevent the repercussions of symptomatic malaria in pregnancy. Despite elimination of severe malaria and mortality in women who attended every week, 48 this strategy has not completely prevented the adverse eff ects of low birthweight and anaemia.
Discussion
Malaria in pregnancy in the Asia-Pacifi c region contrasts with that in Africa because many women are at risk in highly heterogeneous transmission settings. Irrespective of the number of children they have had, most pregnant women have little or no background immunity to malaria, so each infection is potentially fatal to mothers or fetuses. Prevention and treatment are complicated by diff erent vectors, multidrug-resistant parasites (P falciparum and P vivax) and suboptimal dosing of antimalarials, such as artemether-lumefantrine. P vivax can relapse throughout pregnancy when primaquine is contraindicated. The reduced birthweight of fi rst-born babies is similar to that recorded in Africa, but eff ects of symptomatic malaria in pregnancy (maternal death, miscarriage, stillbirth, or premature labour) seem to be more prominent in the Asia-Pacifi c region. Although malaria control and the intro duction of artemisinin-based combination therapies in the general population has resulted in a substantial decline in prevalence of malaria, further eff orts are needed from the national malaria control programmes as fi rst-trimester treatment for P falciparum infection, and effi cacy of chloroquine for P vivax infection • Eff ect of malaria in pregnancy and antimalarial exposure on growth, development, and survival of the fetus, newborns, infants, and young children in longitudinal cohorts • Interactions between malaria, red-cell inherited disorders, co-infections (eg, helminths, HIV, or rickettsia), and nutrient supplementation • Strategies to prevent malaria (P falciparum and P vivax) in at-risk groups such as migrants, or those exposed because of occupation or residential location • Eff ect of malaria in pregnancy on post-partum morbidity and mortality
Search strategy and selection criteria
Reports were identifi ed through searches of PubMed for those published before Jan 10, 2011, with the terms "malaria" and "pregnancy" combined with specifi c country names. The analysis was restricted to English language articles. The Malaria in Pregnancy Consortium library, WHO regional websites, the World Malaria Report, and ClinicalTrials.gov were searched for additional studies of malaria in pregnancy from included countries. We identifi ed national malaria treatment and prevention policies for pregnant women on the websites of each country's Ministry of Health. All regional WHO representatives were approached to include available data from each national malaria programme. Principal investigators of continuing trials in the region were invited to share unpublished data.
and donors, because every infection in pregnancy is detrimental to mother and baby, with repercussions in infancy and childhood. Methods of detection of parasitaemia (peripheral or placental malaria smear, rapid diagnostic tests, or histopathology) underestimate the burden of malaria in pregnancy. Prevalence surveys could show that few women are infected at one timepoint, but cumulative proportions of malaria infections are more useful indicators because of the duration of pregnancy. Of the 126 reports included in this Review (webappendix p 1-4), 107 (85%) came from only three countries (Thailand, India, Papua New Guinea). In many regions of high malaria transmission, no study of malaria in pregnancy has been done or reported in English. Likewise, pharmacokinetic drug fi ndings need confi rmation in distinct populations.
Improved estimates of the morbidity and mortality of malaria in pregnancy calculated from longitudinal cohort data in populations at risk are urgently needed, as are drug-dose-optimisation studies in pregnant women, and implementation of strategies for prevention of malaria in pregnancy (panel). When malaria in pregnancy cannot be readily prevented, accurate diagnosis and prompt treatment with effi cient drugs for any detected parasitaemia are essential to avert dangerous symptomatic disease and to reduce eff ects on fetuses. Indeed, in a recent report of the largest study 152 into the eff ects of malaria and its treatment in the fi rst trimester, both vivax and falciparum malaria contributed signifi cantly to miscarriage. Risk of miscarriage was three-times higher in women with asymptomatic malaria, and four-times higher in those with symptomatic disease, compared with women who did not have malaria. No serious side-eff ects of antimalarial treatments were noted. 152 However, even a safe and eff ective 3 day artemisinin-based combination treatment for women in the second and third trimester is still absent in most countries in the Asia-Pacifi c region. Evidence suggests that dihydroartemisinin-piperaquine is one of the best contenders. The best possible frequency, feasibility, and eff ectiveness of intermittent screening in the antenatal clinic in diff erent settings should be assessed. For example, malaria screening at every antenatal visit could be provided to pregnant women at increased risk for malaria. More work is needed to address the diffi cult question of prevention and treatment of P vivax during pregnancy.
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